Edesa Biotech Stock Retained Earnings
| EDSA Stock | USD 4.47 0.09 2.05% |
Edesa Biotech fundamentals help investors to digest information that contributes to Edesa Biotech's financial success or failures. It also enables traders to predict the movement of Edesa Stock. The fundamental analysis module provides a way to measure Edesa Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Edesa Biotech stock.
| Last Reported | Projected for Next Year | ||
| Retained Earnings | -47.2 M | -44.8 M |
Edesa | Retained Earnings |
Edesa Biotech Company Retained Earnings Analysis
Edesa Biotech's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Edesa Biotech Retained Earnings | (52.42 M) |
Most of Edesa Biotech's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Edesa Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Edesa Retained Earnings Driver Correlations
Understanding the fundamental principles of building solid financial models for Edesa Biotech is extremely important. It helps to project a fair market value of Edesa Stock properly, considering its historical fundamentals such as Retained Earnings. Since Edesa Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Edesa Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Edesa Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Edesa Biotech has a Retained Earnings of (52.42 Million). This is 105.63% lower than that of the Biotechnology sector and 154.1% lower than that of the Health Care industry. The retained earnings for all United States stocks is 100.56% higher than that of the company.
Edesa Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Edesa Biotech's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Edesa Biotech could also be used in its relative valuation, which is a method of valuing Edesa Biotech by comparing valuation metrics of similar companies.Edesa Biotech is currently under evaluation in retained earnings category among related companies.
Edesa Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Edesa Biotech from analyzing Edesa Biotech's financial statements. These drivers represent accounts that assess Edesa Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Edesa Biotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 486.2M | 623.9M | 107.3M | 88.3M | 843.9M | 886.1M | |
| Enterprise Value | 479.2M | 616.2M | 100.2M | 83.0M | 830.5M | 872.0M |
Edesa Fundamentals
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.56 | ||||
| Current Valuation | 9.48 M | ||||
| Shares Outstanding | 3.22 M | ||||
| Shares Owned By Insiders | 28.35 % | ||||
| Shares Owned By Institutions | 10.74 % | ||||
| Number Of Shares Shorted | 15.2 K | ||||
| Price To Earning | (3.96) X | ||||
| Price To Book | 2.46 X | ||||
| Price To Sales | 120,478 X | ||||
| Gross Profit | 311.2 K | ||||
| EBITDA | (9.22 M) | ||||
| Net Income | (8.37 M) | ||||
| Cash And Equivalents | 12.81 M | ||||
| Cash Per Share | 0.83 X | ||||
| Total Debt | 94.49 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 1.85 X | ||||
| Cash Flow From Operations | (6.64 M) | ||||
| Short Ratio | 1.74 X | ||||
| Earnings Per Share | (20.16) X | ||||
| Target Price | 24.0 | ||||
| Number Of Employees | 16 | ||||
| Beta | 0.92 | ||||
| Market Capitalization | 13.86 M | ||||
| Total Asset | 8.89 M | ||||
| Retained Earnings | (52.42 M) | ||||
| Working Capital | 4.61 M | ||||
| Current Asset | 6.92 M | ||||
| Current Liabilities | 581.49 K | ||||
| Net Asset | 8.89 M |
About Edesa Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Edesa Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Edesa Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Edesa Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Edesa Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Edesa Biotech's short interest history, or implied volatility extrapolated from Edesa Biotech options trading.
Pair Trading with Edesa Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edesa Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edesa Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against Edesa Stock
| 0.54 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.41 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.41 | XFOR | X4 Pharmaceuticals Buyout Trend | PairCorr |
The ability to find closely correlated positions to Edesa Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edesa Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edesa Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edesa Biotech to buy it.
The correlation of Edesa Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edesa Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edesa Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edesa Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Edesa Biotech Piotroski F Score and Edesa Biotech Altman Z Score analysis. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Edesa Stock analysis
When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Edesa Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (20.16) | Quarterly Revenue Growth (1.00) | Return On Assets (0.56) | Return On Equity (0.96) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.